Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Single Dose MPCs Injection
Single Dose MPCs · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| High Dose MPCs | EXPERIMENTAL | Injection of High Dose MPCs with Hyaluronic Acid |
| Low Dose MPCs | EXPERIMENTAL | Injection of Low Dose MPCs with Hyaluronic Acid |
| Saline injection | SHAM_COMPARATOR | Injection of saline solution. |
| Hyaluronic acid injection | PLACEBO_COMPARATOR | Injection of hyaluronic acid solution |
| Name | Type | Description |
|---|---|---|
| Single Dose MPCs Injection | BIOLOGICAL | Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus. |
| Single injection of saline solution | PROCEDURE | Intradiscal control injection with saline solution |
| Single injection of hyaluronic acid | PROCEDURE | Intradiscal control injection with hyaluronic acid |
Inclusion Criteria: 1. Male or females at least 18 years of age. 2. Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol. 3. Have the ability to understand and provide written authorization for the use and disclosur...
Top 2 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mesoblast Limited Sponsored ADR | MESO | 1 | PHASE3 | Rexlemestrocel-L |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
Single Dose MPCs is an investigational cell-based therapy developed by Mesoblast Limited for degenerative disc disease, a musculoskeletal condition that causes lumbar back pain. It is given as a single injection and has been studied in a Phase 2 clinical trial. It is not an approved treatment.
Single Dose MPCs is being developed to treat degenerative disc disease, specifically for patients with lumbar back pain. The goal is to provide a single-dose injection that may relieve pain associated with disc degeneration. It remains investigational and has not been approved for any use.
Single Dose MPCs is developed by Mesoblast Limited, an Australian regenerative medicine company. Mesoblast trades on the Nasdaq under the ticker MESO. The company is responsible for the clinical development of this cell therapy candidate.
Single Dose MPCs is in Phase 2 clinical development. The only reported trial for this candidate is a completed Phase 2 study. It is an investigational product and has not received FDA approval.
Single Dose MPCs has been evaluated in one completed Phase 2 trial, NCT01290367, titled "Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain." The trial enrolled 100 participants with degenerative disc disease across the United States and Australia.
Yes, Single Dose MPCs Injection is another name for Single Dose MPCs. Both refer to the same investigational cell therapy developed by Mesoblast Limited for degenerative disc disease. The terms are used interchangeably in reference to this product candidate.